ahaMSCs-Exos — Intranasal Exosome Delivery for Alzheimer's Disease Phase I/II
Intranasal administration bypasses the BBB. No adverse events reported; cognitive improvement on ADAS-cog observed in the mid-dose cohort.
| Trial ID | NCT04388982 ↗ |
|---|---|
| Sponsor | Ruijin Hospital · China |
| Cell Source | 지방 MSC 유래 엑소좀 (AD-MSC-Exo) · allogeneic |
| Indication | 알츠하이머병 · Alzheimer's Disease |
| Phase | PHASE 1 2 |
| Status | COMPLETED |
| Delivery Route | intranasal |
| Enrollment | 9 |
| Publication | General Psychiatry 2023 |
Trial Design
Patients with mild-to-moderate Alzheimer’s disease were assigned to one of three dose cohorts. Exosomes derived from allogeneic human adipose-tissue MSCs (ahaMSCs-Exos) were administered intranasally twice weekly for 12 weeks, followed by follow-up assessments at weeks 16, 24, 36, and 48.
Key Results
No adverse events were reported across any dose cohort. The mid-dose cohort demonstrated a meaningful improvement in ADAS-cog (Alzheimer’s Disease Assessment Scale – Cognitive Subscale) scores; the effect was partly attributed to a slowing in hippocampal atrophy progression.
Clinical Significance
The most important contribution of this trial is the validation of a BBB-bypassing delivery route. The blood-brain barrier (BBB) remains the foremost obstacle in Alzheimer’s disease therapeutics. Although exosomes are known to possess intrinsic capacity to traverse the BBB, the intranasal route was adopted to exploit this property more efficiently. The nasal mucosa provides an anatomical conduit — via the olfactory and trigeminal nerve pathways — through which drugs can be delivered directly to the brain.
This trial also clinically confirms the comparative advantages of exosomes over MSCs themselves: lower immunogenicity, scalable manufacturing from established cell lines, no need for invasive harvesting, and simplified storage.
Limitations
- The sample size of nine patients is too small to draw robust conclusions regarding efficacy.
- No placebo control group was included.
- The observation that efficacy was confined to the mid-dose cohort, with a weaker signal at the high dose, requires mechanistic explanation.
Korean Context
In South Korea, exosomes fall under the Ministry of Food and Drug Safety (MFDS) classification of advanced biopharmaceuticals. Development in combination with an intranasal drug-delivery device may require a separate medical device approval track. Korean companies including ExoCoBio and ILIAS Biologics are advancing exosome clinical programs, with potential to expand into neurological indications.